FLIPI24:新诊断滤泡性淋巴瘤的现代预后模型与临床试验富集工具
FLIPI24模型基于4485例一线免疫化疗的滤泡性淋巴瘤患者开发并内部验证,用于预测24个月事件率;在LEO队列和三项III期试验中外部验证显示,高危组24个月事件率22%-35%、5年OS 77%-83%,低危组分别为10%-12%和96%-97%。
要点
- FLIPI24使用年龄及血红蛋白、LDH、β2微球蛋白、WBC四个血液指标预测24个月事件率。
- 外部验证中高危组24个月事件率22%-35%、5年OS 77%-83%,低危组为10%-12%和96%-97%。
- FLIPI24可于诊断时识别淋巴瘤相关死亡高风险患者,并用于临床试验富集设计。
核心结论
- FLIPI24模型能在诊断时稳健分层,识别淋巴瘤相关死亡风险较高的滤泡性淋巴瘤患者与死亡风险极低者。
研究设计与样本
- FLIPI24模型基于10个观察性队列中4485例接受一线免疫化疗的滤泡性淋巴瘤患者个体数据开发并内部验证。
- 外部验证使用前瞻性观察LEO队列(N=565)和三项随机III期试验(N=3192);扩展至所有一线治疗患者使用LEO队列(N=1445)及其分子流行病学子队列(N=1074)。
主要发现
- 在四个外部免疫化疗验证数据集中,FLIPI24高危患者(占23%-32%)24个月事件率为22%-35%,5年OS为77%-83%。
- FLIPI24低危患者(占29%-31%)24个月事件率为10%-12%,5年OS为96%-97%。
- FLIPI24在验证和扩展数据集中表现一致,且优于现有预后工具。
- 评估淋巴瘤相关死亡及扩展至所有滤泡性淋巴瘤患者时结果一致。
关键数值与推荐
- FLIPI24模型纳入年龄和四个血液变量:血红蛋白、乳酸脱氢酶、β2微球蛋白和白细胞计数。
- 高危FLIPI24患者占外部免疫化疗验证集的23%-32%,24个月事件率22%-35%,5年OS 77%-83%。
- 低危FLIPI24患者占29%-31%,24个月事件率10%-12%,5年OS 96%-97%。
临床怎么用
- FLIPI24可在诊断时用于识别24个月内疾病进展或淋巴瘤相关死亡风险较高的滤泡性淋巴瘤患者。
- FLIPI24可作为临床试验富集工具,用于筛选新诊断滤泡性淋巴瘤的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS: The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION: The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.
引用
- Maurer MJ, Prochazka VK, El-Galaly TC, et al. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. J Clin Oncol. 2025. PMID: 41329901. doi:10.1200/JCO-25-00892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。